| PSP |
|---|
| Full Name | Persephin |
| Category | Gene |
| Path | /genes/psp |
| Chromosome | 19q13.33 |
| Protein | Persephin |
| Family | GDNF family |
PSP (Persephin) is a member of the glial cell line-derived neurotrophic factor (GDNF) family. It was discovered in 1999 and encodes a secreted neurotrophic factor. While less studied than GDNF, Neurturin, and Artemin, persephin has shown promising neuroprotective properties, particularly for motor neurons and dopaminergic neurons.
Persephin mediates its effects through specific receptor interactions:
- Primary receptor: GFRα4 (GDNF Receptor Alpha 4)
- Co-receptor: RET (Rearranged during transfection)
- Binding triggers downstream signaling including:
- PI3K/Akt pathway
- MAPK/ERK pathway
- PLCγ pathway
Persephin has demonstrated neurotrophic activity:
- Motor Neuron Survival: Supports survival and differentiation of motor neurons
- Dopaminergic Neuroprotection: Protects dopaminergic neurons in models of Parkinson's disease
- Renal Development: Essential for ureteric bud development and kidney morphogenesis
- Enteric Neurons: Supports survival of enteric nervous system neurons
Interestingly, persephin has unique properties compared to other GDNF family members:
- GFRα4 has high specificity for persephin
- Some studies suggest weaker trophic effects compared to GDNF for dopaminergic neurons
- May have different therapeutic potential due to distinct receptor binding profiles
Persephin has been investigated as a potential therapeutic:
- Protects dopaminergic neurons in 6-OHDA and MPTP models
- Less likely to cause side effects compared to GDNF (due to more restricted receptor distribution)
- Preclinical studies show promise for neuroprotection
- Amyotrophic Lateral sclerosis (ALS): Persephin has shown protective effects on motor neurons
- Spinal Muscular Atrophy (SMA): May support motor neuron survival
- Congenital kidney malformations in PSP-deficient mice
- Potential therapeutic for renal hypoplasia
PSP shows tissue-specific expression:
- Brain:
- Moderate expression in striatum and substantia nigra
- Lower expression in cortex and hippocampus
- Kidney: High expression during development
- Testis: Expression in developing and adult testis
- Peripheral tissues: Lower expression in heart, lung, skeletal muscle
Persephin represents a promising therapeutic candidate:
- More restricted receptor distribution may reduce side effects
- May not cause weight loss or keloid formation seen with GDNF
- Potential for more targeted delivery
- Limited preclinical data compared to other GDNF family members
- Delivery to the CNS remains challenging
- Requires further clinical validation
- Persephin neuroprotection in Parkinson's disease models (2018)
- GFRα4: A persephin-specific receptor (2001)
- Persephin in motor neuron disease (2019)